Effect of Tuberculosis Preventive Therapy on HIV Disease Progression and Survival in HIV-Infected Adults

REFERENCES

• Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med. 1997;337:725–733.
   PubMed Web of Science ®Google Scholar
• Gulick RM, Mellors JW, Haylir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med. 1997;337:734–739.
   PubMed Web of Science ®Google Scholar
• Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human deficiency virus infection. N Engl J Med. 1998;338:853–856.
   PubMed Web of Science ®Google Scholar
• Hogg RS, O'Shaughnessy MV, Gataric N, et al. Decline in deaths from AIDS due to new antiretrovirals. Lancet. 1997;349:1294.
   PubMed Web of Science ®Google Scholar
• UNAIDS. Report on the global HIV/AIDS epidemic, Decem-ber 2004. Available at: http://www.usaids.org/publica-tions/index.html. Accessed September 1, 2005.
   Google Scholar
• The President's Emergency Plan for AIDS Relief - 5/27/03. Available at: http://www.usaid.gov/our_work/global_health/aids/pepfarfact.html. Accessed September 1,2005.
   Google Scholar
• Yeni PG, Hammer SM, Hirsch MS, Saag MS, et al. Treat-ment for Adult HIV infection. 2004 recommendations of the International AIDS Society-USA Panel. JAMA. 2004; 292:251–365.
   Google Scholar
• Nunn AJ, Kengeya-Keyondo JF, Malamba SS, Seeley JA, Moulder DW. Risk factors for HIV-1 infection in adults in a rural Ugandan community: a population study. mns 1994;8:81–86.
   Google Scholar
• Nunn AJ, Wagner HU, Okongo JM, Malamba SS, Kengeya-Keyondo JF, Moulder DW. HIV-1 infection in a Ugandan town on the trans African highway: prevalence and risk factors Int J srn mns. 1996;7: 123–130.
   Google Scholar
• Morgan D, Maude GH, Malamba SS, et al. HIV-1 disease progression and AIDS-defining disorder in a rural Uganda cohort. Lancet. 1997;350:245–250.
   PubMed Web of Science ®Google Scholar
• Narain JP, Raviglione MC, Kochi A. HIV-associated tuber-culosis in developing countries: epidemiology and strate-gies for prevention. Tuberc Lung Dis. 1992;73: 311–321.
   PubMedGoogle Scholar
• Guelar A, Gate!! JM, Verclgjo J, et al. A prospective study of the risk of tuberculosis among HIV-infected patients. AIDS. 1993;6:1435–1439.
   Google Scholar
• Whalen CC, Johnson JL, Okwera A, Hom DL, Huebner R, et al. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodefi-ciency virus. New Engl J Med. 1997;337:801–808.
   PubMed Web of Science ®Google Scholar
• Johnson JL, Okwera A, Hom DL, Mayanja H, Kityo CM, et al. Duration of efficacy of treatment of latent tuberculosis infection in HIV-infected adults. AIDS. 2001;15:1–11.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Acquired immune deficiency syndrome (AIDS): interim proposal for a WHO staging sys-tem for HIV-1 infection and disease. Wekly Epidemiol Rec. 1990;65:221–228.
   PubMedGoogle Scholar
• Tuner BJ, Markson LE, McKee L, et al. The AIDS-defining diagnosis and subsequent complications: a survival-based severity index. J Acquir Immune Defic Syndr. 1991;4:1059–1071.
   PubMed Web of Science ®Google Scholar
• Mocroft AJ, Johnson MA, Sabin CA, Lipman M, Elford J, et al. Staging system for clinical AIDS patients. Lancet. 1995;346:L12–17.
   PubMed Web of Science ®Google Scholar
• Hanson DL, Chu SY, Farizo KM, Ward JW, et al. Distribu-tion of CD4 T lymphocytes at diagnosis of acquired immu-nodeficiency syndrome-defining and other human immu-nodeficiency virus-related illnesses. Arch Inter Med. 1995;155:1537–1542.
   PubMed Web of Science ®Google Scholar
• Crowe SM, Carlin JB, Stewart KI, Lucas CR, Hoy JF. Predictive value of CD4 lymphocyte numbers for the devel-opment of opportunistic infections and malignancies in HIV-infected persons. J Acquir Immune Defic Syndr. 1991;4: 770–776.
   PubMed Web of Science ®Google Scholar
• Kaplan EL, Meier P. Nonparametric estimation from incom-plete observations. J Am Stat Assoc. 1958;53:457–481.
   Web of Science ®Google Scholar
• Cox DR. Regression models and life tables (with discus-sion). J Royal Stat Soc B. 1972;74:187–220.
   Google Scholar
• SAS Institute Inc. SAS/STAT software. Cary, NC: SAS Insti-tute Inc.
   Google Scholar
• Morgan D, Maude GH, Malamba SS, Okongo MJ, Wagner H-U, et al. HIV-1 disease progression and AIDS-defining disorders in rural Uganda. Lancet. 1997;350: 245–250.
   PubMed Web of Science ®Google Scholar
• Morgan D, Whitworth JAG. The natural history of HIV-1 infection in Africa. Nat Med. 2001;7: 143–145.
   PubMed Web of Science ®Google Scholar
• Del Amo J, Petruckevitch A, Phillips AN, Johnson AM, Stephenson JM, et al. Spectrum of disease in Africans with AIDS in London. AIDS. 1996;10:1563–1569.
   PubMed Web of Science ®Google Scholar
• Del Amo J, Petruckevitch A, Phillips A, Johnson AM, Stephenson J, et al. Disease progression and survival in HIV-1 infected Africans in London. AIDS. 1998;12:1203–1209.
   PubMed Web of Science ®Google Scholar
• Morgan D, Malamba SS, Orem J, Mayanja B, Okongo M, Whitworth JAG. Survival by AIDS defining conditions in rural Uganda. Sex Transm Infect. 2000;76:193–197.
   PubMed Web of Science ®Google Scholar
• O'Dell MW, Lubeck, DP, O'Driscoll P, Matsuno S. Validity of the Karnofsky performance status in an HIV-infected sample. J Acquir Defic Syndr Human Retrovirus. 1995;1: 350–357.
   Google Scholar
• Wenzel T, Pindur G, Morsdorf S, Giacchi J. Influence of HIV-infection on the Karnofsky score and general social functioning in patients with hemophilia. Haemostasis. 1998;28:106–110.
   PubMedGoogle Scholar
• Fantoni M, Izzi I, Borgo D, Forno D, et al. Inter-rater reliabil-ity of a modified Karnofsky scale of performance status for HIV-infected individuals. AIDS Patient Care STDS. 1999;13:23–28.
   PubMed Web of Science ®Google Scholar
• Pezzotti P, Phillips AN, Dorrucci M, et al. Category of exposure to HIV and age in progression to AIDS: longitudi-nal study of 1199 people with known dates of seroconversion. BMJ. 1996;313:583–586.
   PubMed Web of Science ®Google Scholar
• Touloumi G, Karafoulidou A, Gialeraki A, Katsarou O, Milona I, et al. Determinants of progression of HIV infection in a Greek hemophilia cohort followed for up to 16 years after seroconversion. J Acquir Defic Syndr Human Retrovirus. 1998;19: 89–97.
   PubMed Web of Science ®Google Scholar
• Hawken MP, Meme HK, Elliot LC, et al. Isonizid preventive therapy for tuberculosis in HIV-infected adults: results of a randomized controlled trial. AIDS. 1997;11:875–882.
   PubMed Web of Science ®Google Scholar
• Quigley MA, Mwinga A, Hosp M, Lisse I, Fuchs D, et al. Long-term effect of preventive therapy for tuberculosis in a cohort of HIV-infected Zambian adults mns 2001;15: 215–222.
   Google Scholar
• Bucher HC, Griffith LE, Guyatt GH, et al. Isonizid prophy-laxis for tuberculosis in HIV infection: a meta-analysis of randomized controlled trials mns 1999;13: 501–507.
   Google Scholar
• Moreno S, Miralles P, Diaz MD, et al. Isoniazid preventive therapy in human immunodeficiency virus-infected person. Long-term effect on development of tuberculosis and sur-vival. Arch Intern Med. 1997;157:1729–1734.
   Google Scholar
• Pinho AMF, Santoro-Lopes G, Harrison LH, Schechter M. Chemoprophylaxis for tuberculosis and survival of HIV-infected patient in Brazil. AIDS. 200115: 2129–2135.
   Google Scholar
• Pape JW, Jean SS, Ho JL, et al. Effect of Isonizid prophy-laxis on incidence of active tuberculosis and progression of HIV infection. Lancet. 1993;342:268–272.
   PubMed Web of Science ®Google Scholar
• Dolan MJ, Clerici M, Blaatt SP, et al. In vitro T cell function delayed-type hypersensitivity skin testing, and CD4+ T cell subset phenotyping independently predict survival time in patients infected with human immunodeficiency virus. J Infect Dis. 1995;172:79–87.
   PubMed Web of Science ®Google Scholar
• Gordin FM, Hatigan PM, Klimas NG, et al. Delayed-type hypersensitivity skin tests are an independent predictor of human immunodeficiency virus disease progression. J In-fect Dis. 1994;169:893–897.
   PubMed Web of Science ®Google Scholar